Nadja Zaborsky
Overview
Explore the profile of Nadja Zaborsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rinnerthaler G, Egle D, Bartsch R, Schmitt C, Petzer A, Balic M, et al.
Nat Cancer
. 2025 Jan;
6(1):41-50.
PMID: 39820125
The role of anthracyclines in the treatment of early breast cancer (EBC) is increasingly being challenged, especially in de-escalation strategies. However, owing to their immunogenic effects, anthracyclines are promising combination...
2.
Parigger T, Gassner F, Drothler S, Scherhaufl C, Hodlmoser A, Schultheis L, et al.
Technol Cancer Res Treat
. 2024 May;
23:15330338241252706.
PMID: 38766867
In this study, stool samples were evaluated for tumor mutation analysis a targeted next generation sequencing (NGS) approach in a small patient cohort suffering from localized rectal cancer. Colorectal cancer...
3.
Parigger T, Drothler S, Scherhaufl C, Gassner F, Schubert M, Steiner M, et al.
Acta Haematol
. 2024 Feb;
147(5):604-611.
PMID: 38402867
Introduction: Targeting the B-cell receptor pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus...
4.
Hoeger B, Nadolni W, Hampe S, Hoelting K, Fraticelli M, Zaborsky N, et al.
Function (Oxf)
. 2023 Oct;
4(6):zqad053.
PMID: 37786778
Cyclooxygenase-2 (COX-2) is a key regulator of inflammation. High constitutive expression enhances survival and proliferation of cancer cells, and adversely impacts antitumor immunity. The expression of is modulated by various...
5.
Pleyer L, Vaisband M, Drost M, Pfeilstocker M, Stauder R, Heibl S, et al.
Am J Hematol
. 2023 Aug;
98(11):1685-1698.
PMID: 37548390
The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with...
6.
Jansko-Gadermeir B, Leisch M, Gassner F, Zaborsky N, Dillinger T, Hutter S, et al.
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190237
: Next generation sequencing (NGS) has become indispensable for diagnosis, risk stratification, prognostication, and monitoring of response in patients with myeloid neoplasias. Guidelines require bone marrow evaluations for the above,...
7.
Vaisband M, Schubert M, Gassner F, Geisberger R, Greil R, Zaborsky N, et al.
BMC Bioinformatics
. 2023 Apr;
24(1):158.
PMID: 37081386
Accurate somatic variant calling from next-generation sequencing data is one most important tasks in personalised cancer therapy. The sophistication of the available technologies is ever-increasing, yet, manual candidate refinement is...
8.
Pleyer L, Heibl S, Tinchon C, Vallet S, Schreder M, Melchardt T, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900181
In this prospective study (NCT01595295), 272 patients treated with azacitidine completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect modelling was used to incorporate longitudinal data. When compared with a matched...
9.
Akimova E, Gassner F, Greil R, Zaborsky N, Geisberger R
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163016
Chronic lymphocytic leukemia (CLL) is a very common and mostly incurable B-cell malignancy. Recent studies revealed high interpatient mutational heterogeneity and worsened therapy response and survival of patients with complex...
10.
Leb-Reichl V, Kienzl M, Kaufmann A, Stoecklinger A, Tockner B, Kitzmueller S, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34675067
Viral antigens are among the strongest elicitors of immune responses. A significant proportion of the human population already carries pre-existing immunity against several childhood viruses, which could potentially be leveraged...